E
Sell
8/1/2024Downgrade
GeneDx Holdings Corp. (WGS) was downgraded to E+ from D- on 8/1/2024 due to a major decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.7766 to -$1.096, the quick ratio declined from 2.8 to 1.95, and debt to equity increased from 0.27 to 0.29.
D
Sell
3/15/2024Upgraded
GeneDx Holdings Corp. (WGS) was upgraded to D- from E+ on 3/15/2024 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
GeneDx Holdings Corp. (WGS) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
GeneDx Holdings Corp. (WGS) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
GeneDx Holdings Corp. (WGS) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
D
Sell
11/15/2022Upgraded
Sema4 Holdings Corp. (SMFR) was upgraded to D from D- on 11/15/2022 due to a significant increase in the growth index, valuation index and solvency index. Total revenue increased 130.13% from $36.17M to $83.23M, EBIT increased 49.69% from -$162.44M to -$81.72M, and earnings per share increased from -$0.2539 to -$0.2038.
D
Sell
5/31/2022Upgraded
Sema4 Holdings Corp. (SMFR) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.
E
Sell
5/13/2022Downgrade
Sema4 Holdings Corp. (SMFR) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, growth index and valuation index. Earnings per share declined from -$0.1674 to -$0.3147, operating cash flow declined 56.76% from -$51.99M to -$81.49M, and debt to equity increased from 0.04 to 0.05.
D
Sell
5/5/2022Upgraded
GeneDx Holdings Corp. (WGS) was upgraded to D- from E+ on 05/05/2022.
E
Sell
4/20/2022Downgrade
Sema4 Holdings Corp. (SMFR) was downgraded to E+ from D- on 4/20/2022 due to a decline in the solvency index, volatility index and total return index.
D
Sell
3/15/2022Downgrade
Sema4 Holdings Corp. (SMFR) was downgraded to D- from D on 3/15/2022 due to a large decline in the efficiency index, growth index and total return index. Net income declined 228.78% from $31.39M to -$40.43M, earnings per share declined from $0.1307 to -$0.1674, and EBIT declined 29.48% from -$89.6M to -$116.02M.
D
Sell
11/18/2021None
GeneDx Holdings Corp. (WGS) was downgraded to D from U on 11/18/2021.
